|Bid||1.0600 x 1000|
|Ask||1.0900 x 1200|
|Day's Range||1.0900 - 1.2200|
|52 Week Range||1.0200 - 28.8600|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.25|
Subscribe to Yahoo Finance Plus to view Fair Value for AMTI
Top-line data readout anticipated late 2022 or early 2023SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with moderate-to-severe ulcerative colitis (UC). AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule. “Co
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
With the business potentially at an important milestone, we thought we'd take a closer look at Applied Molecular...